4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX

Investors who are interested in high-risk but high-reward sectors are often interested in the biotech sector. Most of the companies in the sector are working on highly innovative products that could eventually end up solving massive healthcare-related issues and thereby become highly profitable.

However, such endeavors may also not be successful consistently. Moreover, the performance of these volatile stocks is often tied to the decisions of the regulatory bodies in the United States and abroad. In this feature, we take a closer look at four biotech stocks that could be worth watching at this point.

CEL-SCI Corporation (NYSEAMERICAN: CVM) – The company is involved in an effort to boost the immune system of a patient prior to surgery, chemotherapy, and radiotherapy. CEL-SCI Corporation believes that such a service could have a major impact on the probability of survival for the patient.

The company’s product, Multikine, was developed with the aim of helping the immune system in targeting a tumor at a time when the immune system may be fully functional. As a consequence, the chances of attacking the tumor with greater effectiveness would also go up significantly.

Last month the company announced that the final registration study for the product had been designed for the sole purpose of confirming efficacy and safety results, which were statistically significant. In addition to that, in the same news release, CEL-SCI Corporation also announced that the study would be concerned with targeting a population of untreated resectable patients at Stage 4 and Stage 3 of head or neck cancer, who did not have involvement of lymph nodes.

Investors ought to know that the company had already completed a Phase 3 trial of the Multikine product, and the study had been completed under randomized control. It could be one of the stocks in the biotech sector that could have considerable upside in the long term.

NKGen Biotech Inc. (Nasdaq: NKGN) – If you are on the lookout for innovative companies in the biotech sector, then NKGen Biotech Inc. could be one to keep an eye on. The clinical-stage biotech company is involved in the development and commercialization of innovative autologous and allogenic NK cell therapeutics.

The company, which is headquartered out of Santa Ana, California, was in the news cycle yesterday after it made an announcement about its common stock listing status. The company revealed that on March 3, 2025, it had received a notification with regards to the fact that the NASDAQ Hearings Panel had decided to delist its common stock from the NASDAQ Global Market after the close of trading on March 4, 2025.

The NKGen Biotech stock was delisted due to the failure to maintain the market value of its common shares. However, the company did make an announcement about the future as well. It was revealed that the stock was going to trade on the OTC Markets Group exchange starting on March 5, 2025. NKGen Biotech went on to note that it intended to start trading on the highest tier of the OTC Markets Group exchanges, the OTCQX.

Nascent Biotech (OTC:NBIO)—Another stock from the biotech space that has gained a degree of traction among seasoned investors in recent days is that of Nascent Biotech Inc.

The clinical-stage biotech firm is involved in leading the development of human monoclonal antibodies, which could then be used in treating a wide range of cancers and eventually help people suffering from those all over the world. Pritumumab, which is Nascent Biotech’s lead candidate, is described by the company as a human monoclonal antibody, which could be moved into the Phase 2 clinical trials for treating those suffering from brain cancer.

Earlier this year, in January, the company announced that it had received a notification from the OTC Markets Group due to its failure to file a quarterly report on Form 10-Q for the fiscal quarter that had ended on September 30, 2023.

In the notification letter, the company was advised that it was not in compliance with the continued listing requirements of the OTC Markets as per the listing criteria that had been laid down. At the time, it was noted that the Nascent Biotech stock was not being quoted on the regular platforms of the OTC Markets. Instead, the stock was being quoted on the ‘Experts Market’ of the OTC Markets.

Immunic Inc. (NASDAQ: IMUX) is another biotech company that has been on the radars of many investors in recent times. The company is involved in the development of a clinical pipeline of orally administered small molecule therapies meant for the treatment of autoimmune and chronic inflammatory conditions.

On March 3, the company announced that it was going to be one of the participants at a series of scientific and investor conferences throughout the course of this month. From March 4 to March 7, it would be a participant at the Annual Meeting of the Society of Virology and at the Leerink Partners Global Healthcare Conference from March 10 to March 12.

On the other hand, on February 26, the company announced that it presented the data pertaining to its lead asset product in a pair of posters at the Americas Committee for Treatment and Research of Multiple Sclerosis Forum 2025. The event took place from February 27 to March 1 at West Palm Beach in Florida. The product in question that was the subject of the poster was IMU 838, a nuclear receptor-related activator.